Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population-based study

Respiratory Research

Volumn 6, Issue , 2005, Pages

  Dahl, Morten ^a   Tybjærg Hansen, Anne ^b,d   Lange, Peter ^c,d   Nordestgaard, Børge G ^a,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MANNOSE BINDING LECTIN; SERINE PROTEINASE INHIBITOR; THYMIDINE; TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; DENMARK; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENE DELETION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITALIZATION; HUMAN; INCIDENCE; INTRON; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RISK ASSESSMENT; SELF REPORT; SPIROMETRY; AGED; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HETEROZYGOTE; MIDDLE AGED; POPULATION GENETICS; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASTHMA; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DENMARK; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETICS, POPULATION; HETEROZYGOTE; HUMANS; INCIDENCE; INTRONS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; WOMEN;

EID: 27644442784     PISSN: 1465993X     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-6-113     Document Type: Article

References (51)

1. Dahl M, Tybjærg-Hansen A, Lange P, Nordestgaard BG: ΔF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet 1998, 351: 1911-1913
2. Tzetis M, Efthymiadou A, Strofalis S, Psychou P, Dimakou A, Pouliou E, et al.: CFTR gene mutations - including three novel nucleotide substitutions - and haplotype background in patients with asthma, disseminated brochiectasis and chronic obstructive pulmonary disease. Hum. Genet. 2001, 108:216-221
3. Hoffjan S, Nicolae D, Ober C: Association studies for asthma and atopic diseases: a comprehensive review of the literature. Resp. Res. 2003, 4: 14
4. Boucher RC: New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 2004, 23: 146-158
5. The Cystic Fibrosis Genetic Analysis Consortium: Worldwide survey of the ΔF508 mutation - report from the cystic fibrosis genetic analysis consortium. Am. J. Hum. Genet. 1990, 47: 354-359
6. Dahl M, Nordestgaard BG, Lange P, Tybjærg-Hansen A: Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion. J. Allergy Clin. Immunol. 2001, 107: 818-823
7. Griesenbach U, Geddes DM, Alton EWFW: The pathogenic consequences of a single mutated CFTR gene. Thorax 1999, 54(suppl 2): S19-S23
8. Chillón M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, et al.: Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med. 1995, 332: 1475-1480
9. Pignatti PF, Bombieri C, Benetazzo M, Casartelli A, Trabetti E, Gilè LS, et al.: CFTR gene variant IVS8-5T in disseminated bronchiectasis. Am. J. Hum. Genet. 1996, 58: 889-892
10. Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M, Yahav Y, et al.: A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am. J. Respir. Crit. Care Med. 1997, 155: 1914-1920
11. Bombieri C, Benetazzo M, Saccomani A, Belpinati F, Gilè LS, Luisetti M, et al.: Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum. Genet. 1998, 103: 718-722
12. Castellani C, Bonizzato A, Pradal U, Filicori M, Foresta C, La Sala GB, et al.: Evidence of mild respiratory disease in men with congenital absence of the vas deferens. Respir. Med. 1999, 93: 869-875
13. Noone PG, Pue CA, Zhou Z, Friedman KJ, Wakeling EL, Ganeshananthan M, et al.: Lung disease associated with the IVS8 5T allele of the CFTR gene. Am. J. Respir. Crit. Care Med. 2000, 162: 1919-1924
14. Noone PG, Knowles MR: 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir. Res. 2001, 2: 328-332
15. Andrieux J, Audrézet MP, Frachon I, Leroyer C, Roge C, Scotet V, et al.: Quantification of CFTR splice variants in adults with disseminated bronchiectasis, using the TaqMan flourogenic detection system. Clin. Genet. 2002, 62: 60-67
16. Lee JH, Choi JH, Namkung W, Hanrahan JW, Chang J, Song SY, et al.: A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases. Hum. Mol. Genet. 2003, 12: 2321-2332
17. Casals T, De-Gracia J, Gallego M, Dorca J, Rodríguez-Sanchón B, Ramos MD, et al.: Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations? Clin. Genet. 2004, 65: 490-495
18. King PT, Freezer NJ, Holmes PW, Holdsworth SR, Forshaw K, Sart DD: Role of CFTR mutations in adult bronchiectasis. Thorax 2004, 357-358
19. Lázaro C, de Cid R, Sunyer J, Soriano J, Giménez J, Álvarez M, et al.: Missense mutations in the cystic fibrosis gene in adult patients with asthma. Hum. Mutat. 1999, 14: 510-519
20. de Cid R, Chomel JC, Lazaro C, Sunyer J, Baudis M, Casals T, et al.: CFTR and asthma in the French EGEA study. Eur. J. Hum. Genet. 2001, 9: 67-69
21. Castellani C, Quinzii C, Altieri S, Mastella G, Assael BM: A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. Genet. Test. 2001, 5: 249-254
22. Marchand E, Verellen-Dumoulin C, Mairesse M, Delaunois L, Brancaleone P, Rahier JF, et al.: Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis. Chest 2001, 119: 762-767
23. Eaton TE, Miller PW, Garrett JE, Cutting GR: Cystic fibrosis transmembrane conductance regulator gene mutations: do they play a role in the aetiology of allerigic bronchopulmonary aspergillosis? Clin. Exp. Allergy 2002, 32: 756-761
24. Friedman KJ, Heim RA, Knowles MR, Silverman LM: Rapid characterization of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: association of the 5T allele with selected CFTR mutations and its incidence in atypical sinopulmonary disease. Hum. Mutat. 1997, 10: 108-115
25. Kiesewetter S, Macek M, Davis C, Curristin SM, Chu CS, Graham C, et al.: A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat. Genet. 1993, 5: 274-278
26. Cuppens H, Teng H, Raeymaekers P, De Boeck C, Cassiman JJ: CFTR haplotype backgrounds on normal and mutant CFTR genes. Hum. Mol. Genet. 1994, 3: 607-614
27. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG: Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat. Genet. 1993, 3: 151-156
28. Teng H, Jorissen M, Van Poppel H, Legius E, Cassiman JJ, Cuppens H: Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells. Hum. Mol. Genet. 1997, 6: 85-90
29. Larriba S, Bassas L, Giménez J, Ramos MD, Segura A, Nunes V, et al.: Testicular CFTR splice variants in patients with congenital absence of the vas deferens. Hum. Mol. Genet. 1998, 7: 1739-1744
30. Mak V, Jarvi KA, Zielenski J, Durie P, Tsui LC: Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens. Hum. Mol. Genet. 1997, 6: 2099-2107
31. Rave-Havel N, Kerem E, Nissim-Rafinia M, Madjar I, Goshen R, Augarten A, et al.: The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am. J. Hum. Genet. 1997, 60: 87-94
32. Manson A, Huxley C: Skipping of exon 9 of human CFTR in YAC-transgenic mice. Genomics 2001, 77: 127-134
33. Delaney SJ, Rich DP, Thomson SA, Hargrave MR, Lovelock PK, Welsh MJ, et al.: Cystic fibrosis transmembrane conductance regulator splice variants are not conserved and fail to produce chloride channels. Nat. Genet. 1993, 4: 426-431
34. Strong TV, Wilkinson DJ, Mansoura MK, Devor DC, Henze K, Yang Y, et al.: Expression of an abundant alternatively spliced form of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is not associated with a cAMP-activated chloride conductance. Hum. Mol. Genet. 1993, 2: 225-230
35. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Høiby N, et al.: Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J. Clin. Invest. 1999, 104: 431-437
36. Mahadeva R, Westerbeek RC, Perry DJ, Lovegrove JU, Whitehouse DB, Carroll NR, et al.: Alpha1-antitrypsin deficiency alleles and the TaqI GA allele in cystic fibrosis lung disease. Eur. Respir. J. 1998, 11: 873-879
37. Frangolias DD, Ruan J, Wilcox PJ, Davidson GF, Wong LTK, Berthiaume Y, et al.: Alpha1-antitrypsin defficiency alleles in cystic fibrosis lung disease. Am. J. Respir. Cell Mol. Biol. 2003, 29: 390-396.
38. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M: The Copenhagen City Heart Study - Østerbroundersøgelsen. Tables with data from the third examination 1991-1994. Eur. Heart J. Suppl. 2001, 3(H): H1-H83
39. Jensen G: Epidemiology of chest pain and angina pectoris, with special reference to treatment needs. Acta Med. Scand. Suppl. 1984, 682: 1-120
40. Lange P, Nyboe J, Jensen G, Schnohr P, Appleyard M: Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur. Respir. J. 1991, 4: 1080-1087
41. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997, 52(suppl. 5): S1-S28
42. 1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann. Intern. Med. 2002, 136: 270-279
43. Dahl M, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG: A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J. Exp. Med. 2004, 199: 1391-1399
44. 3 Leu33Pro homozygosity and risk of cancer. J. Natl. Cancer Inst. 2003, 95: 1150-1157
45. Viel M, Leroy C, Georges MD, Claustres M, Bienvenu T: Novel length variant of the polypyrimidine tract within the splice acceptor site in intron 8 of the CFTR gene: consequences for genetic testing using standard assays. Eur. J. Hum. Genet. 2004 (in press)
46. Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, et al.: Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J. Clin. Invest. 1998, 101: 487-496
47. Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Georges MD, et al.: Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am. J. Hum. Genet. 2004, 74: 176-179
48. Aznarez I, Zielenski J, Siminovitch K, Tsui LC: Increased frequency of CFTR mutations and variants among asthma patients. Pediatr. Pulmonol. 1999, suppl 19: 208
49. Mennie M, Gilfillan A, Brock DJH, Liston WA: Heterozygotes for the delta F508 cystic fibrosis allelele are not protected against bronchial asthma. Nat. Med. 1995, 1: 978-979
50. Schroeder SA, Gaughan DM, Swift M: Protection against brochial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. Nat. Med. 1995, 1: 703-705
51. Schwartz M, Brandt NJ, Koch C, Lanng S, Schiøtz PO: Genetic analysis of cystic fibrosis in Denmark. Implications for genetic counseling, carrier diagnosis and prenatal diagnosis. Acta Paediatr. 1992, 81: 522-526